Page 29 - Pharmaceutical- Guide to Biopharmaceutical
P. 29

Characterization  Quality Control


 Glycan Analysis  RF-20Axs





 Analysis of Glycans by HPLC Detection   benefits

 of Fluorescence-Marked Glycans                                                                                    Cell Line Optimization
 click here            •   The low noise and excellent S/N ratio ensure ample sensitivity for glycan analysis.
                       •   Cell temperature control functionality enables highly reproducible data acquisition.
 Operating Principle and Features  Measurement Method and Conditions
                       •   Standard, semi-micro, inert, and other cells can be selected based on the given analysis.
 Glycans can affect the safety and efficacy of biopharmaceuticals.  One   Glycans in an antibody drug were analyzed by HPLC with detection by
 technique used to analyze glycans is to mark them with fluorescence   the high-sensitivity RF-20Axs fluorescence detector. An Aeris PEPTIDE
 and then analyze them by HPLC using a fluorescence detector.   XB-C18 core-shell analytical column was used. The column packing   Culture
 Shimadzu RF-20Axs fluorescence detectors offer low noise and good S/  material penetration was optimized for analyzing peptides and other
 N levels (compared to previous models, as shown in Fig. 1) to provide   macromolecules, which makes it effective for separating glycans and
 excellent sensitivity and linearity for glycan analysis. Glycan fluorescent   contaminants in antibody drugs.
 labeling methods include those using pyridylamino (PA)-glycan and   Two types of antibody drugs were treated with trypsin and
 2-aminobenzamide (2-AB)-labeled glycan. Either type of fluorescent-  Glycopeptidase F was used to cleave glycans. Then the glycans were
 labeled glycans can be analyzed in the same manner.  fluorescently derivatized by PA and used for analysis (Table 1).
 Results
 RF-20AXS
 S/N:84  Peak differences noticed between the chromatograms for antibody                                           Purification
 drugs A and B after about 50 minutes of elution (*) clearly indicated
 the drugs contained different glycan levels. In addition, many peaks
 with different response levels were observed (Fig. 2 and 3).
 mV
 0.0  0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0  4.5  min  40
 mV  Antibody Drug A
 RF-10AXL  40  *
 (Previous model)  S/N:3  Antibody Drug A
 *                                                                                                                 Characterization





 0
 0.0  0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0  4.5  min
 Fig. 1   Chromatograms of 10 fmol PA-Glycan
 0 0.0  10  20  30  40  50  60  min
 mV  Fig. 2   Chromatogram of PA-Glycans from Antibody Drug A
 Table 1   Analytical Conditions  0.0  10  20  30  40  50  60  min
 40
 Column:  Aeris PEPTIDE XB-C18  mV  Antibody Drug B
 (150 mm × 2.1 mm I.D., 1.7 μm)  40  Specifications                                                                Quality Control
 Mobile phase A:  20 mmol/L Ammonium Formate  Antibody Drug B
 (pH 4.5)  0.0095 % (v/v) Formic acid-water
               Instrument             RF-20Axs fluorescence detector
 Mobile phase B:  20 mmol/L Ammonium Formate
 0.0095 % (v/v) Formic acid-Methanol  Light source  Xenon lamp, low-pressure mercury lamp (To check wavelength accuracy)
 Time Program (B. Conc.):  0 % (0 min) → 5 % (60 min) →
 → 10 % (70 min) →  *  Wavelength range  Excitation wavelength from 200 to 900 nm, Fluorescence wavelength from 200 to 900 nm
 → 100 % (70.01 min- 80 min) →
 → 0 % (95.01 – 110 min)  *  Cell temperature control range  (Room temperature - 10 °C) to 40 °C
 Flowrate:  0.4 mL/min  Cell          Standard conventional cell  Volume: 12 μL  Pressure capacity: 2 MPa
 Column Temp.:  40 °C  0
 Injection Volume:  3 µL              Optional semi-micro cell  Volume: 3 μL   Pressure capacity: 2 MPa
 0 0.0  10  20  30  40  50  60  min
 Detection:  RF-20Axs                                                                                              Pharmacokinetics
 (Ex: 320 nm, Em: 400 nm)             Optional inert cell       Volume: 12 μL  Pressure capacity: 2 MPa
 0.0  10  20  30  40  50  60  min
               Sampling rate          Max. 100 Hz (1 wavelength mode)
 Fig. 3   Chromatogram of PA-Glycans from Antibody Drug B
 Conclusion    Function               Four-wavelength detection, wavelength scanning
    Application Examples (Shimadzu Application News No.)   Operating environment  4 to 35 °C
 Glycans in antibody drugs can be analyzed using HPLC by fluorescent   Dimensions  W 260 mm × D 500 mm × H 210 mm
 labeling the glycans after trypsin digestion. RF-20Axs detectors offer   • Analysis of 2-AB glycans (L483)
 high sensitivity and low noise. They can also be connected to an LC-  • Quantitative analysis of favipiravir spiked in plasma (L570)  Weight  18 kg  Others
 2060 series integrated HPLC system (refer to p. 24).  Power requirement  100 to 240 V AC, 400 VA, 50/60 Hz
 This analysis of glycans in antibody drugs was achieved with help from professor Kenichiro Tadoroki of the Laboratory of Analytical and Bio-Analytical Chemistry, School of Pharmaceutical Sciences, University
 of Shizuoka.

 28                                                                                                               29
 index                                                                                                   index
   24   25   26   27   28   29   30   31   32   33   34